Skip to main
CTNM
CTNM logo

CTNM Market Capitalization Overview

Market Cap: $103.49M as of Jul 2, 2025

$103.49M
Past Month+$8.80M (9.29%)
As of Jul 2, 2025, CTNM has a market capitalization of $103.49M. Over the past 30 days, its market cap has decreased by -13.09%, while in the last 12 months, it has decreased by -72.6%.

Market capitalization represents the total value of Contineum Therapeutics Inc as perceived by the stock market. It is calculated by multiplying the current stock price by the total number of outstanding shares.

CTNM Market Cap Formula = Stock Price * Shares Outstanding

The market cap of CTNM helps investors assess the company's size and compare it with competitors for better investment decisions.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

CTNM Market Cap History

DateMarket CapChange
Jul 1, 2025$99.61M-13.09%
Jun 2, 2025$114.62M+11.59%
May 1, 2025$102.71M-38.54%
Apr 1, 2025$167.13M-1.62%
Mar 3, 2025$169.88M-29.67%
Feb 3, 2025$241.54M-35.29%
Jan 2, 2025$373.27M-4.36%

CTNM End of Year Market Cap History

DateMarket CapChange
2025$103.49M-72.60%
2024$377.65M

FAQs About Contineum Therapeutics Inc (CTNM) Market Cap

As of Jul 2, 2025, the market capitalization of CTNM is $103.49M. Market cap represents the total value of a company’s outstanding shares and is a key indicator of its size in the stock market.

In the last 30 days, Contineum Therapeutics Inc’s market capitalization has increased by 9.29%, changing from $94.69M to $103.49M as of Jul 2, 2025.

In the last 3 months, Contineum Therapeutics Inc’s market capitalization has increased by —, changing from – to – as of –.

In the year 2024, Contineum Therapeutics Inc’s market capitalization increased from – in January to $377.65M in December, reflecting a — change.

Contineum Therapeutics Inc (CTNM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.